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In this review article we examine the role of inﬂammation-related genes in osteoarthritis (OA) from the
perspective of genetics, epigenetics and gene expression. There have been great strides in such genomic
analyses of OA in recent years thanks to the study of adequately powered patient cohorts, the detailed
analysis of candidate genes, and the application of genome-wide approaches. These have led to some
unexpected and therefore exciting discoveries, implicating pathways that would not necessarily have
been predicted to have a role in this common arthritis. Inﬂammatory-related genes sit ﬁrmly in the
candidate camp based on prior observations that the OA disease process can have an inﬂammatory
component. What is clear from the genetic studies published to date is that there is no compelling
evidence that DNA variation in inﬂammatory genes is an OA risk factor. This conclusion may of course
change as ever more powerful association studies are conducted. There is, however, compelling evidence
that epigenetic effects involving inﬂammatory genes are a component of OA and that alteration in the
expression of these genes is also highly relevant to the disease process. We may in fact be close to
demonstrating, at the genomic level, a clear separation of OA patients into those in whom inﬂammation
is a key driver of the disease and those in whom it is not. This has obvious implications for the design of
trials of novel OA interventions and may also guide the intelligent re-purposing of anti-inﬂammatory
therapies.
© 2015 The Authors. Published by Elsevier Ltd and Osteoarthritis Research Society International. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Over the last decade the volume of data derived from the
genomic analysis of osteoarthritis (OA) has escalated almost
exponentially, with the application of genome-wide association
scans (GWASs), comprehensive epigenetic analyses and powerful
gene expression studies. For the majority of these investigations,
the OA phenotype used has been severe disease in the absence of a
secondary cause, such as joint trauma, and in which the disease is
so painful and debilitating that joint replacement has been un-
dertaken. Alternative phenotypes have included injury models, in
particular meniscal tears that can increase the risk of OA develop-
ment. This latter model has been particularly investigated in gene
expression analyses.
For a genetic association study in which trans-generational
heritable DNA changes are being measured as opposed to somatic: J. Loughlin, Newcastle Uni-
al Research Group, 4th Floor
ramlington Place, Newcastle
44-191-208-5455.
in).
r Ltd and Osteoarthritis Research Smutations, the cell source of the genotyped DNA is irrelevant. Blood
is the tissue often used in these studies due to its relative ease of
accessibility, although saliva is now a common alternative. For
epigenetic and gene expression studies the source of the nucleic
acid (DNA and RNA, respectively) can, however, be critical, since
alterations in epigenetic status or gene expression levels can be cell
or tissue-type speciﬁc with the added variability of possible tem-
poral effects. In this regard OA has an advantage over many other
common diseases in that joint replacement surgery provides re-
searches with ready access to relevant tissues, albeit at an end stage
of the disease process. Due to the central nature of cartilage in the
OA disease process, the cartilage chondrocyte has been the
preferred cell for many of the epigenetic and gene expression
studies so far performed. The increasing realization, however, that
OA is a disease of the whole joint1 has encouraged the analysis of a
wider range of joint tissues and cell types. This has the advantage
that a more comprehensive approach is being undertaken in the
molecular analysis of the disease but the complication that, unlike
cartilage, joint tissues such as synovium, fat pad and subchondral
bone contain multiple cell types, adding heterogeneity and there-
fore a further level of complexity to the interpretation of data
derived from these tissues.ociety International. This is an open access article under the CC BY-NC-ND license
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netic and gene expression studies and, where relevant, we shall
also refer to earlier studies where they help to make a point.
OA genetics and inﬂammation-related genes
The use in the not too distant past of underpowered case-
econtrol cohorts in OA genetic studies threw up a large number of
genetic associations. When these studies involved the targeting of
candidate genes, as they invariably did, several pathways emerged
that looked very promising. Amongst there were a number of in-
ﬂammatory genes. However, few of these associations have with-
stood the application of adequately powered analyses, involving
thousands rather than hundreds of OA patients, combined with the
coverage of the whole human genome. These agnostic GWASs have
instead highlighted replicable association signals at or close to
unexpected genes2e9. Recent examples include a hand-OA GWAS
on Icelandic patients that reported an association to ALDH1A2 (P-
value for the association of 3.99  1010), which codes for an
enzyme involved in retinoic acid synthesis3, and hip and/or knee
OA GWASs in European cohorts that reported associations to a
range of genes including CHST11 (P ¼ 1.64  108), which codes for
an enzyme that sulfates proteoglycan6. From amongst the OA as-
sociation signals reported from GWAS none encompass a gene
coding for a protein involved in inﬂammation.
A recent meta-analysis of OA European candidate gene studies
conﬁrmed that the selection of candidates in OA genetic studies is
in fact an extremely fallible exercise, with only the type XI collagen
gene COL11A1 and the vascular endothelial growth factor gene VEGF
demonstrating any semblance of association to the disease from
among the 199 candidates examined10. However, even their asso-
ciation P-values were much less compelling than the signals that
have emerged so far from the GWAS studies, with values >1106.
The inﬂammation-related genes amongst the 199 candidates
studied included those coding for tumor necrosis factor and the NF-
kB protein complex, as well as several coding for interleukins and
their receptors and antagonists. None of these merited particular
comment in that report.
This overwhelming lackof support for inﬂammationas a repository
of OA genetic risk is tempered by one study, reported in 2010 and
involving a GWAS of knee OA in Japanese patients11. Here an associa-
tion to the HLA class II/III region was identiﬁed, with a P-value of
6.73  108 in the Japanese and a P-value of 5.10  109 in a meta-
analysis of Japanese and Europeans. The European contribution to
this P-value was, however, quite modest, whilst subsequent attempts
to replicate the signal in both Asians and Europeans has proven fruit-
less12,13. It appears possible therefore that this association is restricted
to the Japanese cohort that was the source of the initial discovery.
So what to conclude? Apart from this Japanese study, there is at
present no compelling evidence that DNA polymorphismwithin or
near to genes that code for proteins involved in inﬂammation is a
risk factor for OA. That, however, is not the end of the story. The
GWAS and meta-analyzed candidate studies performed to date
have focused on common DNA polymorphisms, with minor allele
frequencies >10%. It is therefore possible that future analyses of less
common polymorphisms will uncover associations to inﬂamma-
tory genes. It is also the case that the caseecontrol sample sizes
studied to date are too small to detect particularly small-effect risk
alleles (odds ratios < 1.1). Since OA is known to be highly polygenic
and lacks large effect loci8 it will be the case that as more powerful
OA GWAS studies are undertaken new risk alleles will be identiﬁed.
It may be that inﬂammatory genes will be amongst these new
discoveries. Finally, the analysis of alternative OA phenotypes (for
example, different compartments of the knee rather than studying
knee OA as a single entity) may reﬁne the association studies anduncover association signals in inﬂammatory genes relevant to
particular OA subsets.
At present, however, the conclusion to draw is that there is no link
between OA genetic risk alleles and inﬂammation-related genes.
OA epigenetics and inﬂammation-related genes
Epigenetic modiﬁcations are a mitotically heritable means by
which the cell can regulate gene expression in the absence of an
alteration in the sequence of the DNA. There are three known
epigenetic mechanisms: DNA CpG methylation, histone modiﬁca-
tions and microRNAs (miRNAs). The ﬁrst two alter the accessibility
of the DNA within the chromatin, inﬂuencing the binding of trans-
acting factors and thereby modulating the initiation and level of
gene transcription. miRNAs regulate the stability of mRNA tran-
scripts and therefore regulate translation rather than transcription.
Several informative review and commentary articles have been
published recently on the role of epigenetics in OA14e18. Most OA
epigenetic studies have focused on candidate loci, often those
coding for catabolic regulators of cartilage homeostasis. As more
high-throughput technologies have been developed, particularly
the use of arrays for CpG methylation analysis, a more genome-
wide approach has been adopted, akin to changes observed in ge-
netics with the shift from candidates to GWAS. Epigenetic effects on
inﬂammatory genes in OA have been convincingly demonstrated
using both the candidate gene and genome-wide approaches, and
below we shall provide examples for each of these.
Candidate studies
Altered CpG methylation of the promoter of the pro-
inﬂammatory interleukin-1b gene IL1B, with concurrent changes
in its expression, has been consistently demonstrated19,20. These
experiments involved the direct study of chondrocytes from OA
patients and in vitro analyses including the forced de-methylation
of the chondrocyte DNA with the agent 5-azacytidine. The role of
histone modiﬁcations in OA has been investigated by examining
the effect of histone deacetylase inhibitors (HDACi) on cartilage
explants and chondrocytes from OA patients. These studies have
revealed that histone acetylation/deacetylationmodulates cartilage
catabolism genes, in particular the matrix metalloproteinases
(MMPs), in response to IL121. The potential utility of this discovery
has been demonstrated in the destabilization of the medial
meniscus (DMM) mouse OA model, with HDAC inhibition attenu-
ating the disease process22.
Genome-wide approaches
Most miRNA studies performed in OA have started with a
microarray-based approach to agnostically assess which miRNAs
are up or down regulated in the disease, followed by a more tar-
geted analysis. A classic example of this is the discovery that
miR140 expression is reduced in OA cartilage and is also down-
regulated following IL-1b stimulation of chondrocytes23. Subse-
quent studies have demonstrated that other miRNAs induce or are
induced by inﬂammatory proteins, including miRNAs 145, 127-5p
and 146a24e26.
Genome-wide CpG methylation analyses in OA have been per-
formed using arrays that enable the investigation of up to several
hundred thousand CpGs. There has so far been six suchmethylation
analyses reported, ﬁve investigating DNA extracted from hip or
knee cartilage27e31 and one investigating DNA extracted from
trabecular bone32. Of the ﬁve cartilage studies numerous compar-
isons were made, including hip vs knee, OA vs non-OA, and carti-
lage adjacent to the lesion vs intact cartilage distal to the lesion.
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ontology analysis performed to identify gene families and pathways
demonstrating signiﬁcant clustering. Four of the ﬁve studies re-
ported inﬂammation-related genes as among the most signiﬁcant
pathways identiﬁed28e31. Intriguingly, two of these four studies
reported that knee OA patients and hip OA patients each segregate
into clusters based on the differential methylation of inﬂammation-
related genes. These results suggest that OA patients can be strat-
iﬁed on the basis of the methylation status of these genes in their
cartilage, implying that inﬂammation is relevant to the disease in
some but not necessarily all OA patients. The trabecular bone study
compared OA samples with those from osteoporotic patients32.
Inﬂammation was not one of the pathways identiﬁed as demon-
strating differential CpG methylation between the two groups.
OA gene expression and inﬂammation-related genes
Through the application of gene-expression microarrays, tran-
scriptomic analyses are identifying unique expression patterns of
inﬂammation-related genes in OA, not only in comparison with
non-OA controls, but also according to the stage of disease pro-
gression, and in the study of healthy and diseased regions of the
same tissue. Below we review the gene expression data with
respect to these three categories.
OA-speciﬁc differences in inﬂammation-related gene expression
Clear differences in inﬂammatory gene expression have been
identiﬁed in the OA joint compared to non-OA controls, with one of
the most overtly inﬂamed tissues being the synovium. Inﬂammation
is less pronounced in the OA synovium in comparison to rheumatoid
arthritis (RA) but correlateswith both pain and structural decline33,34.
While the precise cause of synovium inﬂammation (synovitis) re-
mains to be deﬁned, gene-expression microarray analysis shows
increased expression of complement effector genes and a decrease of
complement inhibitors in the OA synovium compared to controls35.
Further to this, IL-1b has been associated with many of the patho-
logical features ofOA. Although IL1R, encoding the IL-1 receptor, is not
differentially expressed in normal compared to OA synovial ﬁbro-
blasts, IL-1R is upregulated at theprotein level inOA36. IL-1b signaling
has been shown to modulate expression of 909 out of 3459 genes in
primary human articular chondrocytes, including signiﬁcant induc-
tion of numerous chemokines and inﬂammatory mediators, such as
thegenes IL11andCCL537. Thispost-transcriptionalupregulationof IL-
1R in OA is therefore likely to cause a signiﬁcant alteration in in-
ﬂammatory gene expression. In line with this, comparison of OA
cartilage to microscopically intact cartilage from individuals without
OA identiﬁed a distinct upregulation of chemokine and cytokine
genes in OA cartilage, including IL8 and LIF38.
Expression changes in inﬂammatory-associated genes in carti-
lage have been shown to display commonality between knee and
hip OA when compared to non-diseased controls39. For example,
differential expression of genes in the TREM1 signaling pathway,
involved in ampliﬁcation of the inﬂammatory response, occurs in
both knee and hip OA articular cartilage when compared with
controls. In addition to localized tissue-speciﬁc differences in gene
expression, systemic elevation of inﬂammatory gene expression is
also present in OA. Microarray analysis of peripheral blood leuko-
cytes (PBLs) from OA patients and non-OA controls identiﬁed dif-
ferential expression of 173 genes, including many inﬂammatory
genes40. Furthermore, a subgroup of OA patients displayed
increased expression of IL1B of >2 fold when compared with con-
trols. Not only does this provide support for systemic inﬂammation
in OA, but it also supports the notion that a subgroup of OA patients
may exist, for whom inﬂammation is a key disease driver.Early changes in inﬂammatory gene expression
There is an expanding body of research reporting differential
inﬂammatory gene expression in relation to disease progression.
The unique inﬂammatory transcriptome in early OA is of particular
interest as this precedes structural joint damage and as such, may
potentially provide an option for effective therapeutic intervention.
The study of early OA is troublesome, given that clinical symptoms
generally do not occur until cartilage destruction has already
begun. Consequently, studies often focus on groups with highly
increased disease risk. TheMulticentre Osteoarthritis Study (MOST)
longitudinal caseecontrol study reported that meniscal tears are a
key risk factor for developing radiographic OA41. This suggests that
joint trauma can catalyze the molecular changes underpinning
later OA development. Microarray analysis of patients undergoing
arthroscopic menisectomy following a meniscal tear identiﬁed 266
genes to be differentially expressed in inﬂamed synovium
compared with synovium without inﬂammation42. Chemokines
and chemokine receptors, required in innate immune activation,
demonstrated the highest upregulation in inﬂamed synovium. In
particular, expression of CCL5, a CeC chemokine able to recruit
innate immune cells such as lymphocytes, was found to associate
with severity of inﬂammation, as validated by real-time PCR. CCL5
induces IL-6 expression in a concentration-dependent manner in
synovial ﬁbroblasts via interaction with the CCR5 receptor, which
displayed elevated mRNA expression in OA compared to normal
synovial ﬁbroblasts43. As such, it is suggested that this early upre-
gulation of inﬂammatory chemokine expression is pivotal in
inducing cytokine expression, which may be required to instigate
the processes leading to downstream OA-pathology.
The unique early chemokine signature in the damaged joint is
highly dynamic. A pilot analysis of gene expression in synovial ﬂuid
from individuals who had suffered meniscal injury identiﬁed signiﬁ-
cant changes in gene expression dependent on duration of injury44.
Molecular characterization of synovial cell pellets and cell-free su-
pernatant, by microarray and RNA-sequencing, respectively, revealed
a distinct inﬂammatory expression pattern according to injury dura-
tion. In cell pellets, there was increased expression of inﬂammatory
genes in the longer injury duration group (>2 months since injurious
event), with the top 5% of genes with the greatest average expression
belonging to inﬂammatory pathways. The cell supernatant analysis
identiﬁed 764 differentially expressed genes, with SLC2A9 displaying
the greatest differential expression. While not directly involved in
inﬂammatory pathways, this regulator of glucose homeostasis is
induced by OA-associated inﬂammatory cytokines, such as IL-1b, and
may have a role in chondrocyte survival45. This therefore indicates
that even at the very earliest stage of injury, altered inﬂammatory
gene expression may have downstream functional implications.
Analysis of synovium from patients with conﬁrmed early-stage
OA, evidenced by knee pain and cartilage abnormality with a
KellgreneLawrence (KeL) score of <2, supports these molecular
ﬁndings. In synovial membrane biopsies obtained during arthro-
scopic menisectomy, TNF, IL1B and IL6 gene expression levels in
both synovial membrane and synovial ﬂuid were at comparable
levels in early OA and end-stage disease synovium46. This again
demonstrates that changes in the inﬂammatory gene expression
proﬁle are an early event in OA pathogenesis.Focal differences in inﬂammatory gene expression: damaged vs
undamaged tissue
As discussed, gene expression data has provided evidence for
tissue-wide inﬂammatory gene dysregulation in OA. Further to this,
a distinct inﬂammatory gene expression pattern is also apparent at
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lishing why speciﬁc regions of cartilage are affected in OA.
Amicroarray comparison of lesioned and unlesioned cartilage in
individuals with knee OA found 754 genes to be differentially
expressed, with an enrichment of inﬂammatory genes47. Interest-
ingly, genes involved in the complement system, such as C2, were
found to be upregulated in unlesioned cartilage, possibly reﬂecting
altered responsiveness of the lesioned regions. A more powerful
microarray study identiﬁed differential expression of 1717 genes in
33 lesioned and unlesioned knee-OA cartilage pairs, including
many inﬂammatory genes48. CD55, coding for a regulator of the
complement response, was one of the most differentially expressed
genes. Increased gene expression was reﬂected by elevated protein
levels, suggestive of downstream functional consequences of
abnormal focal inﬂammatory gene regulation. This conﬁrmed a
previous in-joint microarray analysis of ﬁve patients undergoing
knee arthroplasty49. A total of 411 differentially expressed genes
were identiﬁed, yet CD55 was one of only six genes consistently
upregulated in the lesioned group, as validated by quantitative real-
time PCR in ﬁve additional specimen pairs. Increased CD55
expression in damaged tissue may initially seem as somewhat of a
paradox, as it is a negative regulator of the complement system.
However, loss of Cd55 in mice ameliorates symptoms in a collagen-
induced model of RA, with signiﬁcant reduction in inﬂammatory
symptoms such as paw swelling50. CD55 is known to function as a
ligand for CD97, present on leukocytes, although the inﬂammatory
implications of the CD55eCD97 interaction remain to be estab-
lished. Given that OA presents from a genetically diverse disease
population, this reproducible evidence implies core inﬂammatory
genes to be integral to disease pathology.
In light of the fact that all tissues in the joint display pathologic
changes in OA, it is to be expected that focal inﬂammatory gene
dysregulation is not limited to cartilage. Microarray analysis of
inﬂamed vs macroscopically normal synovium from 12 patients
with knee OA identiﬁed 886 genes to be differentially expressed,
with an enrichment of inﬂammatory genes. TREM1 demonstrated
particularly increased expression in inﬂamed synovium, validated
by western blot analysis51. Earlier research comparing lesioned and
unlesioned cartilage from knee OA also identiﬁed TREM1 to be
signiﬁcantly upregulated in damaged cartilage52. More commonly
associated with RA, TREM1 expression is induced by activation of
toll like receptor 4 (TLR4) in response to acute inﬂammation, and
results in expression of pro-inﬂammatory cytokines including TNF-
a and IL-1b53. Together, these data provide evidence of focal dys-
regulation of inﬂammatory genes in damaged OA tissues, with a
level of commonality between different tissue types. This may
indicate that early universal dysregulation of a small group of in-
ﬂammatory genes in damaged tissue is essential to the global
pathologic events in the progression of OA.
Genes and OA treatments
Current guidelines recommend topical non-steroidal anti-
inﬂammatory drugs (NSAIDs) and paracetamol as a ﬁrst-line
treatment for OA ahead of oral NSAIDs, with the Osteoarthritis
Research Society International (OARSI) recommending topical
NSAID use in those who do not respond to paracetamol54. This
reﬂects the risk of cardiovascular and gastrointestinal adverse
events posed by NSAIDs, which is signiﬁcantly greater when taken
orally55,56. Conﬂicting data has been published when comparing
the effectiveness of NSAIDs and paracetamol for patients with se-
vere pain, which could be argued to be suggestive of a variable
inﬂammatory contribution in different OA groups57,58. As such,
further research characterizing the role of inﬂammation in OA may
have important bearing on future treatment stratiﬁcation.The ability therefore to identify at a genetic level OA patients for
whom inﬂammation is a core disease modulator may prove
fundamental in advancing pharmacologic intervention and facili-
tating the formation of differential treatment pathways. This would
protect patients less likely to respond well to oral anti-
inﬂammatory treatment from the risk of signiﬁcant adverse ef-
fects, while improving the risk-beneﬁt ratio in the inﬂammatory
subgroup, in favor of increased beneﬁts. The risks of adverse effects
from NSAIDs are also increased by extended periods of use55,56.
Therefore, the future potential to intervene during early stages of
the disease when aberrant inﬂammation is initiated may create the
opportunity for short-term intervention, halting disease progres-
sion while minimizing adverse effects.
Conclusions
From an epigenetic and gene expression perspective,
inﬂammation-related genes have a clear role in the OA disease
process. Most epigenetic and gene expression studies performed to
date have focused on cartilage or synovial tissue. Future analyses
should expand the repertoire to other tissues of the synovial joint
and should also increase sample sizes from the tens of patients
studied so far to the hundreds. This will provide the comprehensive
coverage and power needed to establish the clearest picture
possible of exactly how inﬂammation-related genes contribute to
OA initiation and development. The recent discovery of a circu-
lating miRNA correlating with OA progression59 and of the differ-
ential expression between OA and healthy age-matched controls of
peripheral blood genes60 highlights that a joint-centric approach to
OA may also have to be rethought.
One of the most exciting ﬁnds from the epigenetic analyses is
that OA patients can be stratiﬁed into those inwhom inﬂammation-
related genes are actively involved in OA and those in whom they
appear not to be. This has clear relevance to the design of clinical
trials for testing disease-modifying treatments and to the potential
re-purposing of anti-inﬂammatory drugs: the right treatment for
the right patient.
From a genetic perspective inﬂammation-related genes are not
relevant to the disease, with no compelling evidence that DNA
polymorphism at these genes contributes to OA susceptibility. As
noted earlier, this picture may change as ever more powerful ge-
netic association studies are performed. There is, however, a lot of
catching-up to do and considering that these genes have already
received quite considerable attention it is hard to imagine that they
will emerge as major repositories of OA genetic risk.
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